Meeting
2014 Breast Cancer Symposium
The effect of trastuzumab therapy on clinical benefit from fulvestrant treatment for metastatic estrogen receptor-positive breast cancer patients.
Authors
Mahmoud Charif
University of Cincinnati Cancer Institute, Cincinnati, OH
Mahmoud Charif , Elyse E. Lower , Diane Kennedy , Harriet Kumar , Shugufta Khan , Neetu Radhakrishnan , Xiaoting Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Risk Assessment, Prevention, Early Detection, Screening, and Systemic Therapy
Track
Systemic Therapy,Risk Assessment, Prevention, Early Detection, and Screening
Sub Track
HER2+
Citation
J Clin Oncol 32, 2014 (suppl 26; abstr 155)
DOI
10.1200/jco.2014.32.26_suppl.155
Abstract #
155
Poster Bd #
E2
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer.
First Author: Oana Cristina Danciu
Poster
2019 ASCO Annual Meeting
Lasofoxifene as a potential treatment for ER+ metastatic breast cancer.
First Author: Muriel Laine
Poster
2014 ASCO Annual Meeting
Enobosarm: A targeted therapy for metastatic, androgen receptor positive, breast cancer.
First Author: Beth Overmoyer
Poster
2023 ASCO Annual Meeting
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).
First Author: Erica L. Mayer